Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis www.biorxiv.org/content/10.1101/2024.10.02.616293v1

Immunotherapy with nebulized pattern recognition receptor agonists restores severe immune paralysis and improves outcomes in mice with influenza-associated pulmonary aspergillosis https://www.biorxiv.org/content/10.1101/2024.10.02.616293v1

Influenza-associated pulmonary aspergillosis (IAPA) is a potentially deadly super-infection in patie

📃Scientific paper: Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): A comparison with influenza associated aspergillosis (IAPA) ➡️ Continued on ES/IODE

New research reveals that COVID-19-associated pulmonary aspergillosis (CAPA) affects 0.4%–2.7% of severe COVID-19 patients in Japan. www.news-medical.net/news/2024092...

Incidence and risk factors of an invasive fungal lung infection among COVID-19 patients

Study reveals 0.4%-2.7% incidence of COVID-19-associated pulmonary aspergillosis in severe patients, highlighting significant mortality risks and risk factors.

Povinho de aspergillosis

"The study highlights that COVID-19-associated pulmonary aspergillosis (CAPA) is a serious complication for patients with severe COVID-19 in Japan." onlinelibrary.wiley.com/doi/10.1111/...

Incidence and risk factors for coronavirus disease 2019‐associated pulmonary aspergillosis using administrative claims data

Background Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is one of the noticeable complications of COVID-19 and its incidence varies widely. In Japan, research on the.....

Study highlights COVID-19-related disease in Japan. COVID-19-associated pulmonary aspergillosis. "This severe lung infection, which has been the focus of a few studies in Japan, has been reported internationally to occur in 3.8% to 35% of cases." www.techexplorist.com/study-highli...

Study highlights COVID-19-related disease in Japan

The pioneering research conducted by the team from Osaka Metropolitan University, Japan on the Incidence of COVID-19.

Ugh, sounds really hard. Any idea what initial trigger was (rsv or covid perhaps?). You should be on long lasting salmetrol/fluticasone inhaler 2x/day, every day x 1 year to prevent recurrence & help now. Maybe atropine inhaler too. And rule out aspergillosis, HEPA house air filter. DM w questions.

On the private capital side, here's a $100m round for UK antifungal company F2G Ltd., whose olorofim is in late-stage development for aspergillosis: f2g.com/press-releas...

F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the US | F2G.

Financing is being led by new investor AMR Action Fund with strong participation from new investor ICG Life Sciences and existing investors MANCHESTER, Unit ...

Epidermal Growth Factor Receptor Signaling Governs the Host Inflammatory Response to Invasive Aspergillosis www.biorxiv.org/content/10.1101/2024.09.10.612305v1

Epidermal Growth Factor Receptor Signaling Governs the Host Inflammatory Response to Invasive Aspergillosis https://www.biorxiv.org/content/10.1101/2024.09.10.612305v1

The epidermal growth factor receptor (EGFR) has been identified as an epithelial cell receptor for M

Epidermal Growth Factor Receptor Signaling Governs the Host Inflammatory Response to Invasive Aspergillosis www.biorxiv.org/content/10.1101/2024.09.10.612305v1

Epidermal Growth Factor Receptor Signaling Governs the Host Inflammatory Response to Invasive Aspergillosis https://www.biorxiv.org/content/10.1101/2024.09.10.612305v1

The epidermal growth factor receptor (EGFR) has been identified as an epithelial cell receptor for M